Published in BMC Cancer on October 18, 2009
Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci U S A (2012) 0.96
Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer (2013) 0.93
MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLoS One (2012) 0.93
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget (2016) 0.90
EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation. Proc Natl Acad Sci U S A (2013) 0.86
SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med (Berl) (2012) 0.85
Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia (2013) 0.85
EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol (2013) 0.84
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. J Cancer (2016) 0.78
Aberrant promoter methylation of SH3GL2 gene in vulvar squamous cell carcinoma correlates with clinicopathological characteristics and HPV infection status. Int J Clin Exp Pathol (2015) 0.75
A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika (1965) 14.16
Structure of the alpha beta tubulin dimer by electron crystallography. Nature (1998) 11.07
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol (2002) 6.35
Data mining in bioinformatics using Weka. Bioinformatics (2004) 6.06
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 4.76
A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics (2005) 4.57
Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature (2002) 3.99
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol (1990) 2.60
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer (2007) 2.34
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics (2003) 2.28
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol (1996) 1.66
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer (2008) 1.66
Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A (1996) 1.65
Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res (1999) 1.60
Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet (2000) 1.59
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics (2007) 1.57
Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract (2005) 1.57
Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene (1990) 1.53
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res (2006) 1.52
EVI1 and hematopoietic disorders: history and perspectives. Gene (2005) 1.44
Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer (2007) 1.34
Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem (2007) 1.26
High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia (2005) 1.22
Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer (2008) 1.20
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res (2003) 1.14
Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther (2002) 1.13
Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene (2006) 1.13
The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol (2003) 1.10
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer (2006) 1.10
The complicated copy number alterations in chromosome 7 of a lung cancer cell line is explained by a model based on repeated breakage-fusion-bridge cycles. Cancer Genet Cytogenet (2008) 1.03
Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer (1996) 1.01
Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer (2004) 0.98
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol (1997) 0.97
Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol (2008) 0.97
Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet (2005) 0.93
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer (2006) 0.91
Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol (2008) 0.90
Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res (2005) 0.90
Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett (2008) 0.89
Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol (2003) 0.89
High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cytogenet Genome Res (2009) 0.88
High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer (2008) 0.87
Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell (2001) 0.85
Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet (2007) 0.85
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res (2006) 2.76
Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro. Endocrinology (2010) 1.71
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. J Nucl Med (2009) 1.69
Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res (2010) 1.41
Combining functional and topological properties to identify core modules in protein interaction networks. Proteins (2006) 1.36
Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol (2011) 1.36
Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat (2011) 1.24
Differentiating human embryonic stem cells express a unique housekeeping gene signature. Stem Cells (2007) 1.18
Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells (2008) 1.16
A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int (2011) 1.10
Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer (2006) 1.10
Generation and analysis of 9792 EST sequences from cold acclimated oat, Avena sativa. BMC Plant Biol (2005) 1.03
Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol (2009) 1.03
Artificial intelligence techniques for bioinformatics. Appl Bioinformatics (2002) 1.03
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer (2008) 1.03
Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril (2008) 1.02
External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. Int J Radiat Oncol Biol Phys (2011) 1.01
Isolation and characterization of a Lysinibacillus strain B1-CDA showing potential for bioremediation of arsenics from contaminated water. J Environ Sci Health A Tox Hazard Subst Environ Eng (2014) 1.00
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer (2006) 0.99
Putative cold acclimation pathways in Arabidopsis thaliana identified by a combined analysis of mRNA co-expression patterns, promoter motifs and transcription factors. BMC Genomics (2007) 0.99
Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer (2006) 0.98
Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer (2004) 0.98
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res (2003) 0.98
Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol (2013) 0.97
A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer (2009) 0.96
Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer (2008) 0.94
ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci (2008) 0.94
Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer (2010) 0.94
Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet (2005) 0.93
Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet (2008) 0.91
Economic valuation for sustainable development in the Swedish coastal zone. Ambio (2005) 0.90
Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model. Cancer Cell Int (2009) 0.87
Formation and barrier function of tight junctions in human ovarian surface epithelium. Biol Reprod (2004) 0.87
Validation of suitable endogenous control genes for expression studies of miRNA in prostate cancer tissues. Cancer Genet Cytogenet (2010) 0.87
In silico analysis of promoter regions from cold-induced genes in rice (Oryza sativa L.) and Arabidopsis thaliana reveals the importance of combinatorial control. Bioinformatics (2009) 0.86
Nonrandom pattern of chromosome aberrations in 17beta-estradiol-induced rat mammary tumors: indications of distinct pathways for tumor development. Genes Chromosomes Cancer (2007) 0.85
Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet Cytogenet (2007) 0.84
Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet (2006) 0.84
Regulation of 'stemness' and stem cell differentiation by microRNAs. IDrugs (2009) 0.83
Expression of microRNAs and their target mRNAs in human stem cell-derived cardiomyocyte clusters and in heart tissue. Physiol Genomics (2010) 0.83
Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. Acta Obstet Gynecol Scand (2008) 0.82
Differences in microRNA expression during tumor development in the transition and peripheral zones of the prostate. BMC Cancer (2013) 0.82
High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer. Cancer Genet Cytogenet (2010) 0.82
Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas. Anticancer Res (2010) 0.82
Transcriptional profiling of human embryonic stem cells differentiating to definitive and primitive endoderm and further toward the hepatic lineage. Stem Cells Dev (2010) 0.82
Identification of a gene expression signature for survival prediction in type I endometrial carcinoma. Gene Expr (2010) 0.82
Bioremediation of hexavalent chromium (VI) by a soil-borne bacterium, Enterobacter cloacae B2-DHA. J Environ Sci Health A Tox Hazard Subst Environ Eng (2015) 0.82
Monocyte chemotactic protein-1 (MCP-1), its receptor, and macrophages in the perifollicular stroma during the human ovulatory process. Fertil Steril (2008) 0.82
Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clin Proteomics (2013) 0.81
Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. Clin Proteomics (2012) 0.80
Tight junction formation in epithelial ovarian adenocarcinoma. Acta Obstet Gynecol Scand (2007) 0.80
Deriving evolutionary tree models of the oncogenesis of endometrial adenocarcinoma. Int J Cancer (2007) 0.79
External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer (2009) 0.79
Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer. Int J Gynecol Cancer (2012) 0.79
Classification of information fusion methods in systems biology. In Silico Biol (2009) 0.79
Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention. Anticancer Res (2003) 0.78
A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol (2011) 0.78
Cardiomyogenic gene expression profiling of differentiating human embryonic stem cells. J Biotechnol (2007) 0.78
External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study--quality-of-life analysis. Int J Gynecol Cancer (2012) 0.77
Validation of suitable endogenous control genes for quantitative PCR analysis of microRNA gene expression in a rat model of endometrial cancer. Cancer Cell Int (2013) 0.77
BAC CGH-array identified specific small-scale genomic imbalances in diploid DMBA-induced rat mammary tumors. BMC Cancer (2012) 0.77
Accuracy of intraoperative gross visual assessment of myometrial invasion in endometrial cancer. Acta Obstet Gynecol Scand (2011) 0.76
Classification of tumor samples from expression data using decision trunks. Cancer Inform (2013) 0.76
beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. Cancer Lett (2005) 0.76
Early inflammatory response in epithelial ovarian tumor cyst fluids. Cancer Med (2014) 0.75
A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles. Oncol Lett (2013) 0.75
Evaluation of combining several statistical methods with a flexible cutoff for identifying differentially expressed genes in pairwise comparison of EST sets. Bioinform Biol Insights (2008) 0.75
Network Properties for Ranking Predicted miRNA Targets in Breast Cancer. Adv Bioinformatics (2010) 0.75
Improved survival with clinical guidelines? Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998. Acta Obstet Gynecol Scand (2005) 0.75
Gene Ontology-based semantic alignment of biological pathways by evolutionary search. J Bioinform Comput Biol (2008) 0.75
Usefulness of current risk groups in the treatment of surgically staged endometrial carcinomas; a population-based study from Western Sweden. Anticancer Res (2009) 0.75